Maintenance therapy for advanced stomach cancer after first treatment
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This trial tests a combination of two drugs, fruquintinib and a PD-1 inhibitor, as maintenance treatment after initial chemotherapy for advanced stomach or gastroesophageal junction cancer. It aims to see if this maintenance approach helps keep the cancer from growing. It is for patients with stable disease or better after first-line therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery.
- You have not received any systemic chemotherapy for this advanced cancer before, except as part of your initial treatment plan.
- You have completed first-line chemotherapy and have not had your cancer grow or spread further (at least stable disease).
- Your tumor tests show it is microsatellite stable (MSS) or mismatch repair proficient (pMMR), and is HER2 negative.
- You have at least one measurable tumor lesion as per standard criteria (RECIST 1.1).
- Your blood counts, liver and kidney function are adequate, and you are generally fit (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and FOLFOX chemotherapy) as the first treatment for advanced gastric (stomach) cancer. The goal is to see if this combination is safe and effective in shrinking tumors or slowing the cancer's growth.
This trial tests a combination of two drugs (one targeted therapy and one immunotherapy) given with chemotherapy before and after surgery for stomach cancer that hasn't spread far. The goal is to see if this approach can improve outcomes for people with locally advanced disease.
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
This study tests a combination of two medications (Sac-TMT and fruquintinib) as a second-line treatment for advanced stomach cancer. The goal is to see if this combination can help shrink tumors or slow the cancer's growth after a first treatment has stopped working.
This trial tests a combination of immunotherapy (PD-1 inhibitor), a targeted drug (fruquintinib), and chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that is HER2-negative. It aims to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.